Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
NHS National Framework Agreement for the supply of Lanadelumab. The framework agreement will commence on 1.1.2020 for a period of 12 months, with options to extend for a further 36 months.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| Shire Pharmaceuticals Ltd | 02031674 | £4,844,000 | - |
Government spending data: This supplier has received £1,511,082 in 43 payments (over £25k) from Manchester University NHS Foundation Trust, East Sussex Healthcare NHS Trust (2018-09-13 to 2022-01-26). View full payment history →